These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37150034)

  • 1. The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
    Gao Y; Su X; Xue T; Zhang N
    Biomed Pharmacother; 2023 Jul; 163():114598. PubMed ID: 37150034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells.
    Liu J; Yang K; Zhou L; Deng J; Rong G; Shi L; Zhang X; Ren J; Zhang Y; Cao W
    Int Immunopharmacol; 2024 Nov; 141():112794. PubMed ID: 39137626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease.
    Liu J; Ren J; Zhou L; Tan K; Du D; Xu L; Cao W; Zhang Y
    J Ethnopharmacol; 2024 Nov; 334():118517. PubMed ID: 38972525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
    Wang E; Wang L; Ding R; Zhai M; Ge R; Zhou P; Wang T; Fang H; Wang J; Huang J
    Pharmacol Res; 2020 Jul; 157():104831. PubMed ID: 32339782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
    Hu Y; Tang W; Liu W; Hu Z; Pan C
    Drug Des Devel Ther; 2022; 16():1605-1620. PubMed ID: 35669284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
    You LZ; Lin YX; Fang ZH; Shen GM; Zhao JD; Wang TT
    Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4700-4706. PubMed ID: 29493134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
    Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
    BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress.
    Ji C; Luo Y; Zou C; Huang L; Tian R; Lu Z
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):53. PubMed ID: 30176914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese herbal medicine and its active compounds in attenuating renal injury
    Liu P; Zhu W; Wang Y; Ma G; Zhao H; Li P
    Front Endocrinol (Lausanne); 2023; 14():1142805. PubMed ID: 36942026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
    Zhang Y; Tao C; Xuan C; Jiang J; Cao W
    Oxid Med Cell Longev; 2020; 2020():9542165. PubMed ID: 32855769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research review on the pharmacological effects of astragaloside IV.
    Li L; Hou X; Xu R; Liu C; Tu M
    Fundam Clin Pharmacol; 2017 Feb; 31(1):17-36. PubMed ID: 27567103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells.
    Qi W; Niu J; Qin Q; Qiao Z; Gu Y
    Cell Stress Chaperones; 2014 Jan; 19(1):105-14. PubMed ID: 23719694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
    Ju Y; Su Y; Chen Q; Ma K; Ji T; Wang Z; Li W; Li W
    Biomed Pharmacother; 2019 Jan; 109():84-92. PubMed ID: 30396095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research progress on the antitumor effects of astragaloside IV.
    Zhou R; Guo T; Li J
    Eur J Pharmacol; 2023 Jan; 938():175449. PubMed ID: 36473596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis.
    Zhang M; Liu W; Liu Y; Zhang Z; Hu Y; Sun D; Li S; Fang J
    DNA Cell Biol; 2023 Oct; 42(10):594-607. PubMed ID: 37751175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV.
    Xu Z; Zhou H; Zhang Y; Cheng Z; Wan M; Qin W; Li P; Feng J; Shao S; Xue W; Guo H; Liu B
    Biomed Pharmacother; 2023 Dec; 168():115752. PubMed ID: 37875045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research progress of astragaloside IV in the treatment of atopic diseases.
    Yu S; Peng W; Qiu F; Zhang G
    Biomed Pharmacother; 2022 Dec; 156():113989. PubMed ID: 36411656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease.
    Chen X; Li X; Cao B; Chen X; Zhang K; Han F; Kan C; Zhang J; Sun X; Guo Z
    Int Urol Nephrol; 2024 Feb; 56(2):571-582. PubMed ID: 37552392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.
    Du N; Xu Z; Gao M; Liu P; Sun B; Cao X
    Drug Des Devel Ther; 2018; 12():3517-3524. PubMed ID: 30425453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
    Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
    J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.